Henlius Biotech shareholders reject take-private offer from China's Fosun

Reuters
22 Jan

Jan 22 (Reuters) - Shareholders of Shanghai Henlius Biotech rejected Chinese conglomerate Fosun International's offer to buy the Hong Kong-listed drugmaker, the companies said on Wednesday.

(Reporting by Aaditya Govind Rao in Bengaluru; Editing by Savio D'Souza)

((Aaditya.GovindRao@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10